Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database

C. S. Karapetis, H. Liu, M. J. Sorich, L. D. Pederson, E. Van Cutsem, T. Maughan, J. Y. Douillard, C. J. O’Callaghan, D. Jonker, C. Bokemeyer, A. Sobrero, C. Cremolini, B. Chibaudel, J. Zalcberg, R. Adams, M. Buyse, M. Peeters, T. Yoshino, A. de Gramont, Q. Shi

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database'. Together they form a unique fingerprint.

Medicine & Life Sciences